Caspofungin prophylaxis reduced cases of invasive fungal disease during chemotherapy
Upending an interim analysis that suggested futility, caspofungin (Cancidas) proved superior to fluconazole (Diflucan) as antifungal prophylaxis for children and young adults with leukemia, a randomized trial indicated.
Among over 500 acute myeloid leukemia (AML) patients undergoing intensive chemotherapy, the cumulative incidence of either probable or confirmed invasive fungal disease at 5 months was 3.1% among those on caspofungin compared with 7.2% for those on fluconazole (HR 0.37, 95% CI 0.15-0.94, P=0.03), reported Brian Fisher, DO, MSCE, of the Children’s Hospital of Philadelphia, and colleagues.
Credit: CDC
The post Antifungals Go Head-to-Head in Pediatric Leukemia Trial appeared first on Healthier Environment Living Program.